Portuguese pharmaceutical company Bluepharma has invested EUR 30 million to produce potent oral drugs in solid form in one of the largest industrial units in Europe.
Bluepharma, that is located in Coimbra in Central Portugal, was the first Portuguese pharmaceutical company to be FDA approved for export to the US market. The drugs produced in the new unit will decrease dependence on Asian countries and will ensure that the supply chain for critical medicines will be within EU borders.
With the recent scarcity of essential drugs, this new production unit is strategic, with quality products to be produced while being competitive on the international market. Bluepharma will be producing potent drugs, including in the field on oncology, and is expecting an annual production of 300 million units for generics.
The pharmaceutical group, that is comprised of 20 companies, exported more than 90% of its output to over 100 multinationals in 40 countries in 2022.
#pharmaceuticalinvestmentsportugal #pharmaceuticalsportugal #Bluepharma #genericsportugal #portugalnews #portugalbusinessnews